Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Paris Kids Cancer: Bringing Together Research to Better Understand and Treat Pediatric Cancers
National Integrated Research Program in Pediatric Oncology
Paris Kids Cancer brings together healthcare facilities, research organizations, universities, and parent associations around a common goal: to accelerate progress in the fight against cancers in children and adolescents. Led by AP-HP, Gustave Roussy, and the Institut Curie, this multi-site center brings together basic, translational, and clinical research to better understand these diseases, develop new treatment strategies, and improve quality of life during and after treatment.
-
5 years
certification
-
6 million euros
of the announced total budget
-
15
cast members gathered
-
3
parent organizations
Why Paris Kids Cancer?
Pediatric cancers encompass a wide range of rare and heterogeneous diseases. Their biology may differ from that of adult cancers, which necessitates research specifically designed for children and adolescents. The rarity of each disease also makes it essential to pool expertise, data, and biological resources.
Paris Kids Cancer was created to provide a common framework for this research. The program aims to facilitate collaboration among biologists, clinicians, data specialists, and researchers from other disciplines, so that the knowledge generated in the laboratory can be explored and then evaluated in appropriate clinical trials.
Integrated research, from the laboratory to the clinic
-
Basic Research
Understanding the biological mechanisms underlying pediatric cancers and their progression.
-
Translational Research
Translating laboratory findings into hypotheses, tools, or strategies that can be evaluated in patients.
-
Clinical Research
To evaluate, within structured protocols, new treatments, combination therapies, or care pathways.
Key Scientific Directions
The initial research projects announced are organized around several complementary areas, aimed at better characterizing pediatric tumors and opening up new avenues of research.
|
Cellular Plasticity and Reprogramming Studying the ability of cancer cells to alter their function and adapt, particularly in response to treatment. |
Immunotherapies Exploring new strategies that mobilize the immune system against cancers in children and adolescents. |
|
Biomarkers Identifying biological characteristics that may help better understand the disease, its progression, or the response to treatments. |
Data and Bioinformatics Integrating clinical, genomic, phenotypic, epidemiological, immunological, and social data to support research and the development of personalized treatment approaches. |
An approach open to many disciplines
The program combines oncology, hematology, biology, immunology, and genetics with other fields such as the physical sciences, chemistry, mathematics, computer science, epidemiology, public health, and the humanities and social sciences. This approach aims to study not only the mechanisms of disease but also treatments and their individual, family, and social consequences.
Curing More, but Also Curing Better
Improving survival rates is not the only goal of pediatric oncology research. Paris Kids Cancer also incorporates long-term follow-up of individuals who have been cured of childhood cancer, in order to better understand the long-term effects of the disease and treatments, and to identify any medical, psychological, and social needs that may persist.
The Role of Organizations
Three organizations are participating in the program: Imagine for Margo, the Hubert Gouin Enfance et Cancer Association, and the Laurette Fugain Association. Their involvement helps bridge the gap between scientific priorities and the real-life needs of children, adolescents, and their families.
Shared Governance
The center is headed by Dr. Olivier Delattre. Prof. Véronique Minard-Colin and Prof. André Baruchel serve as deputy directors. This leadership team brings together complementary expertise in biological research, pediatric oncology, immunology, and pediatric hematology.
|
Dr. Olivier Delattre Director of Paris Kids Cancer |
Prof. Véronique Minard-Colin Deputy Director |
Prof. André Baruchel Deputy Director |
Fifteen organizations united in the Île-de-France region
Paris Kids Cancer brings together three lead institutions, universities and research organizations, partner centers, and three parent associations.
| AP-HP | Gustave Roussy |
| Curie Institute | Cordeliers Research Center |
| Imagine Institute | CEA |
| Inserm | CNRS |
| Paris Cité University | Paris-Saclay University |
| PSL University | Sorbonne University |
| Imagine for Margo | Hubert Gouin Childhood and Cancer Association |
| Laurette Fugain Association |
A center accredited under the PEDIACRIEX23 program
Paris Kids Cancer is one of three multi-site centers selected following the National Cancer Institute’s PEDIACRIEX23 call for applications. The designation is valid for five years, and the center will receive a total budget of six million euros.
A national program
Paris Kids Cancer is part of a broader French initiative to establish an integrated research framework in pediatric oncology. It also aims to collaborate with other national and European centers working on cancers affecting children and adolescents.
Frequently Asked Questions
No. It is a multi-site research center that brings together institutions and teams already involved in pediatric oncology care and research.
No. Participation in a study depends on a specific protocol, eligibility criteria, and appropriate information provided to the patient and their family.
Pediatric cancers are rare and highly diverse. Collaboration makes it possible to bring together more expertise, data, and resources to study each disease.
Yes. Long-term follow-up of adults who were cured of childhood cancer is one of the research areas announced.